Valve stenosis

Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

Retrieved on: 
Wednesday, October 7, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Branches of biology, Anatomy, Biology of bipolar disorder, Valve stenosis, Medical specialties, Aortic stenosis, Inositol phosphate, Stenosis, Aortic valve, Inositol

Inositec , a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.

Key Points: 
  • Inositec , a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.
  • Currently CEO of New Amsterdam Pharma, Dr. Davidson was previously the founding CEO and Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk.
  • We are truly honored to have Michael join our Board of Directors.
  • Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions.

Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

Retrieved on: 
Monday, May 4, 2020
Biotechnology, Pharmaceutical, Health, RTT, Branches of biology, Circulatory system, Chemistry, Aortic stenosis, Calcification, Inositol phosphate, Aortic valve, Cardiovascular disease, Inositol, Valve stenosis, Monckeberg's arteriosclerosis

Calcification, particularly in arterial walls and cardiac valves, leads to high cardiovascular morbidity and mortality.

Key Points: 
  • Calcification, particularly in arterial walls and cardiac valves, leads to high cardiovascular morbidity and mortality.
  • Inositec is developing INS-3001 for a number of cardiovascular indications caused by calcification, including aortic valve stenosis.
  • U.S. patent number 10,624,909 covers specifically the composition of matter and use of inositol derivatives for conditions related to pathological calcium crystallization.
  • Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions.

Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications

Retrieved on: 
Wednesday, February 5, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Anatomy, Branches of biology, Histopathology, RTT, Circulatory system, Biomineralization, Calcification, Calcium, Aortic stenosis, Aortic valve, Stenosis, Valve stenosis

INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.

Key Points: 
  • INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.
  • Inositec is developing INS-3001 for a number of cardiovascular indications caused by calcification, including aortic valve stenosis.
  • It potently stabilized calciprotein particle growth and consistently demonstrated low micromolar activity in different in vitro models of cardiovascular calcification.
  • INS-3001 also largely abolished the development of cardiovascular calcification in rodent models, while not causing toxicity related to serum calcium chelation.

Surgical Theater's Precision VR® featured during Late-Breaking Science Sessions at the Transcatheter Valve Therapies 2019 Structural Heart Summit

Retrieved on: 
Thursday, June 13, 2019
RTT, Circulatory system, Cardiovascular system, Valvular heart disease, Valve stenosis, Aortic valve, Aortic stenosis, Atrial fibrillation, Heart, Cardiac surgery

Dr. Castellanos collected feedback from patients after each experienced a 360VR consultation using Precision VR by Surgical Theater for aortic valve stenosis or atrial fibrillation.

Key Points: 
  • Dr. Castellanos collected feedback from patients after each experienced a 360VR consultation using Precision VR by Surgical Theater for aortic valve stenosis or atrial fibrillation.
  • The results were powerful and demonstrated that the use of 360VR enhanced patient education, increased patient satisfaction and understanding and increased surgical conversion.
  • Attendees at TVT in Chicago can observe Dr. Castellanos' moderated poster presentation during the Late-Breaking Science Session on July 13th at 4:15pm.
  • Precision VR is proven to increase patient satisfaction, improve patient engagement, surgical plans and a hospital's financial performance

Boston Scientific Receives FDA Approval for LOTUS Edge™ Aortic Valve System

Retrieved on: 
Tuesday, April 23, 2019
Anatomy, Medicine, Heart, Heart valves, Aortic stenosis, RTT, Valvular heart disease, Cardiac surgery, Stenosis, Valve stenosis, Aortic valve, Boston Scientific

MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System.

Key Points: 
  • MARLBOROUGH, Mass., April 23, 2019 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge Aortic Valve System.
  • The LOTUS Edge valve system is the only FDA-approved aortic valve that gives physicians the option to reposition and completely recapture the valve once it has been fully deployed.
  • The FDA approval of the LOTUS Edge valve system adds to the Boston Scientific suite of Structural Heart product solutions including the SENTINEL Cerebral Protection System and the WATCHMAN Left Atrial Appendage Closure Device available in the U.S., as well as the ACURATE neo Aortic Valve System* in Europe.
  • Aortic valve stenosis is the process of thickening and stiffening in the valve, which can result in an abnormal narrowing of the aortic valve opening and reduction in blood flow.

Global Aortic Valve Stenosis Clinical Trials Review, H2 2018 by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Monday, February 25, 2019
Health, Cardiology, Pharmaceutical, Health, Medicine, Valvular heart disease, Valve stenosis, Cardiac surgery, Aortic stenosis, Clinical trial, Stenosis, Heart valve

The "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Aortic Valve Stenosis Global Clinical Trials Review, H2, 2018" provides an overview of Aortic Valve Stenosis clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Aortic Valve Stenosis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Transcatheter Aortic Valve Implantation (TAVI Devices) (Cardiovascular Devices) - Global Market Analysis and Forecast Model

Retrieved on: 
Thursday, December 27, 2018
Medicine, Circulatory system, Heart, Cardiac surgery, Percutaneous aortic valve replacement, Aortic valve, Aortic stenosis, Heart valve, Valve stenosis, Cardiology, Marjan Jahangiri, Hybrid cardiac surgery

Transcatheter Aortic Valve Implantation (TAVI Devices) (Cardiovascular Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

Key Points: 
  • Transcatheter Aortic Valve Implantation (TAVI Devices) (Cardiovascular Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • Transcatheter Aortic Valve implantation is used in patients who are elderly or are at a high risk for surgery and have severe symptomatic aortic valve stenosis.The number of patients who suffer from aortic stenosis is steadily increasing due to changing demographics.
  • - SWOT analysis for Transcatheter Aortic Valve Implantation market.
  • - Competitive dynamics insights and trends provided for Transcatheter Aortic Valve Implantation market.